Current risk assessment focuses on family history alone.2 However, this does not help to identify men at increased risk of developing non-familial prostate cancer.
If your patient is considering a PSA test, consider taking a wholistic view of their clinical, family and genetic risk factors to make more informed health plan decisions.
Average risk patients may benefit from lifestyle measures to further reduce risk.
Patients at increased risk can also benefit from lifestyle changes to reduce risk of developing prostate cancer. You can also discuss the risks and benefits of additional screening and surveillance measures with this patient.
All patients should be aware of their body and advised to contact their medical practitioner if they experience any unusual or persistent symptoms.
Register as a provider; our team will provide clinical education and other resources as needed.
We will send kits to your clinic to have on hand.
Discuss geneType™ with your patient.
Would geneType™ help them qualify for additional risk reduction strategies?
Complete the Test Requisition form, collect a saliva sample from the patient with the collection kit provided and return both to Rhythm.
You will have the option to use a paper requisition, or a secure, compliant portal to complete the ordering process.
Leave the rest to us.
We will notify you when your patient’s results are ready.
You will have the option to request a consult with a genetic counsellor, whether to review your patient’s results and/or to follow-up with your patient, as needed.
GeneType reports are structured to make the results easy to interpret and communicate to a patient.
The GeneType for Prostate Cancer report includes:
If your question is not shown here, please Contact us directly.
geneType™ for Prostate Cancer is a prostate cancer risk assessment test for men aged 30 years or older.
GeneType for Prostate Cancer is currently validated in men of Caucasian descent and relies on the patient correctly reporting their ethnicity. The risk model incorporates ethnicity-specific polygenic risk scores and population incidence data for patients of African, Asian and Caucasian descent derived from AIHW incidence and mortality data for prostate cancer, however, the model has not been fully validated in all populations yet.
Cancer is a multifactorial disease and there are many different risk factors. Of these, geneType integrates the most predictive risk factors into the model. Future models may include additional risk factors as the scientific community’s understanding of prostate cancer continues to evolve.
This test is not applicable to men who have personal history of prostate cancer or who have already been shown to have a cancer mutation, for example in the BRCA1 or BRCA2 gene, or a diagnosis of a genetic syndrome that may be associated with elevated risk of prostate cancer.
No. This risk assessment does not test for hereditary cancer associated genes. geneType is a risk assessment for asymptomatic men in the general population who are either ineligible for hereditary genetic testing, or who have come back as negative carriers following hereditary testing.
*Patient eligibility dependent on personal medical history, age and sex
A combination of geneType tests for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type 2 diabetes in a single test.
Know your risk of a serious disease to tailor a personalised prevention plan with your medical practitioner.
1. American Cancer Society Prostate Cancer Screening Recommendations. Accessed June 2022.
2. Rawla P. World J Oncol 2019;10:63–89.
Accredited For Compliance With NPAAC Standards And ISO 15189
